NasdaqGS:ZYMEBiotechs
A Look At Zymeworks (ZYME) Valuation After Fast Track Win And New CFO Appointment
Fast Track designation and CFO appointment refocus attention on Zymeworks
The latest catalyst for Zymeworks (ZYME) is a pair of developments: an FDA Fast Track designation for its ZW191 antibody drug conjugate in platinum resistant ovarian cancer, and the appointment of Kristin Stafford as Chief Financial Officer.
See our latest analysis for Zymeworks.
At a share price of $25.80, Zymeworks has seen a 7.1% 30 day share price return and 6.7% 7 day gain, while the 1 year total shareholder return...